<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4649">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03046407</url>
  </required_header>
  <id_info>
    <org_study_id>ChineseASZQ-004</org_study_id>
    <nct_id>NCT03046407</nct_id>
  </id_info>
  <brief_title>Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells</brief_title>
  <official_title>Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project intends to transplant human embryonic stem cells derived retinal pigment
      epitheliums into subretinal space of patients to treat dry age-related macular
      degeneration(dry-AMD).And we will assess the safety and efficacy of RPE transplants to treat
      dry AMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project intends to transplant human embryonic stem cells derived retinal pigment
      epitheliums into subretinal space of patients to treat dry age-related macular
      degeneration(dry-AMD). Through the statistical analysis EDTRS, BCVA, OCT, ERG, Fluorescein
      angiography, Ophthalmic AB ultrasound changes between before and after the treatment to
      assess the safety and efficacy of RPE transplants to treat dry AMD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerance of transplantation</measure>
    <time_frame>12 months</time_frame>
    <description>The safety and tolerance of transplantation of hESC-derived RPE will be considered safe: no above moderate adverse events or severe adverse events which related to transplantation of retinal pigment epithelial cells ; Cells without infectious; No tumorigenicity. Through the clinical signs of subjects and laboratory examination to judge the tolerance, integrity, repellency of RPE cells, and monitoring the presence of local or systemic infection, and presence of metastatic tumor cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy:Early treatment of diabetic retinopathy eye chart (ETDRs)</measure>
    <time_frame>12 months</time_frame>
    <description>Visual function measure: change in visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy：Best corrected visual acuity（BCVA）</measure>
    <time_frame>12 months</time_frame>
    <description>Visual function measure: change in visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy：Optical coherent tomography (OCT)</measure>
    <time_frame>12 months</time_frame>
    <description>Visual function measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy：fundus autofluorescence</measure>
    <time_frame>12 months</time_frame>
    <description>Transplant and host retina integrity and survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy：vision inspection</measure>
    <time_frame>12 months</time_frame>
    <description>Changes of judgment after transplantation of patient's visual field</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Dry Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>retinal pigment epithelium transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>retinal pigment epithelium transplantation</intervention_name>
    <description>Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).</description>
    <arm_group_label>retinal pigment epithelium transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 55-75 years;

          -  Diagnosed as atrophic age-related macular degeneration;

          -  No CNV;

          -  The BCVA of target eye will not be better than 20/200;

          -  Diopter is smaller than -8.00 D, axial length ≤28 mm;

          -  voluntary as test subjects, signed informed consent, regular follow-up on time.

        Exclusion Criteria:

          -  The macular atrophy caused by other diseases in addition to AMD;

          -  With history of other eye diseases or ocular traumas;

          -  With history of intraocular surgery;

          -  With serious system diseases, ALT/AST)&gt; 1.5 or creatine &gt; 1.3 mg/dL;

          -  With any immunodeficiency disease;

          -  Subject who are receiving immunosuppressive therapy;

          -  Allergic to tacrolimus or Mycophenolate mofetil;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhou Qi, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of zoology, Chinese academy of sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang Liu, Doctor</last_name>
    <phone>+86-01064807858</phone>
    <email>wangliu@ioz.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hao Jie, Doctor</last_name>
    <phone>+86-01062558737</phone>
    <email>haojie@ioz.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of Zhengzhou university</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wan guang ming, Doctor</last_name>
      <phone>0371-66862213</phone>
      <email>wgm6608@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Li fu zhen, Doctor</last_name>
      <phone>0371-66862213</phone>
      <email>fuzhenlii@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>February 2, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Qi Zhou</investigator_full_name>
    <investigator_title>Deputy director of Institute of zoology, chinese academy of sciences, and vice president of medical school， University of chinese academy of sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
